This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down
by Zacks Equity Research
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.
BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.
Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 138.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on sales numbers of Pfizer's (PFE) COVID-19 vaccine and COVID pill, Paxlovid.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.
What's in Store for Gilead (GILD) This Earnings Season?
by Zacks Equity Research
Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.
Why Is Editas (EDIT) Down 19.5% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
by Zacks Equity Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.